Hims & Hers Health, Inc. (NYSE:HIMS) Sees Large Drop in Short Interest

Key Points

• Short interest fell by 14.3% to 71,359,926 shares as of March 31, equal to 36.3% of the stock and a short-interest ratio of 2.5 days, signaling a notable reduction in bearish positioning.
• Insiders sold a total of 129,889 shares (~$3.23M) this quarter — including sales by CFO Oluyemi Okupe and COO Michael Chi — while insiders still own 13.71% and institutional investors (led by Vanguard, Capital World and Farallon) now hold 63.52%.
• An FDA review of wellness peptides has become a potential catalyst, helping lift sentiment and analyst activity and sending the stock up 6.5% to $28.74 on heavy volume, though the consensus rating remains Hold with a $31.86 average price target.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) was the target of a large decline in short interest in March. As of March 31st, there was short interest totaling 71,359,926 shares, a decline of 14.3% from the March 15th total of 83,286,092 shares. Based on an average daily volume of 28,538,083 shares, the short-interest ratio is currently 2.5 days. Currently, 36.3% of the company's stock are sold short.

Insiders Place Their Bets

In other news, CFO Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $23.77, for a total transaction of $219,088.09. Following the transaction, the chief financial officer owned 318,789 shares in the company, valued at $7,577,614.53. The trade was a 2.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Chi sold 97,289 shares of Hims & Hers Health stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $2,402,065.41. Following the transaction, the chief operating officer owned 407,282 shares in the company, valued at $10,055,792.58. This trade represents a 19.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 129,889 shares of company stock worth $3,230,986. Company insiders own 13.71% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company's stock worth $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Capital World Investors increased its position in shares of Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company's stock worth $1,065,399,000 after purchasing an additional 223,892 shares during the last quarter. Farallon Capital Management LLC increased its position in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock worth $609,561,000 after purchasing an additional 2,533,271 shares during the last quarter. State Street Corp increased its position in shares of Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company's stock worth $237,210,000 after purchasing an additional 132,311 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company's stock worth $183,485,000 after purchasing an additional 608,950 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on HIMS shares. Morgan Stanley cut their target price on Hims & Hers Health from $40.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 24th. Truist Financial restated a "hold" rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $25.00 to $28.00 and gave the company a "hold" rating in a research note on Tuesday, March 10th. Needham & Company LLC upgraded Hims & Hers Health from a "hold" rating to a "buy" rating and set a $30.00 target price on the stock in a research note on Monday, March 9th. Finally, Barclays boosted their target price on Hims & Hers Health from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, March 11th. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Hims & Hers Health presently has an average rating of "Hold" and a consensus price target of $31.86.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: FDA moves to review restricted peptides — The U.S. FDA has begun a formal review process and scheduled advisory meetings to consider whether several popular wellness peptides can be manufactured by compounding pharmacies, a change that could broaden the market opportunity for HIMS. Read More.
• Positive Sentiment: Analysts and coverage lift on peptide catalyst — Bank of America raised its price target to $25 (while keeping a Neutral rating), citing the FDA step as a potential long-term tailwind for peptide revenue. That upgrade helped validate the thesis that peptides could materially expand HIMS’ addressable market. Read More.
• Positive Sentiment: Heavy options and share volume denote bullish positioning — Unusually large call-option activity and above-average share trading have accompanied the rally, signaling speculative and institutional interest around the peptide story and near-term catalysts. (reported market data)
• Neutral Sentiment: Q4 earnings context — Recent earnings coverage shows revenue growth and an EPS beat, but mixed margin and cash-flow commentary means fundamentals still matter; the peptide news is a strategic upside rather than an immediate earnings driver. Read More.
• Negative Sentiment: Near-term upside may be limited — Several articles note that while the stock jumped on the regulatory pivot, recent earnings-estimate revision trends and the fact that regulatory change is early-stage could limit sustained upside until clearer commercial pathways and timeline are confirmed. Read More.
• Negative Sentiment: Regulatory and execution risk remain — Even if peptides are reclassified for compounding, commercialization, pricing, and margin mix are uncertain; analysts emphasizing these risks could cap multiple expansion until concrete product/partner announcements arrive. Read More.

Hims & Hers Health Stock Up 6.5%

NYSE HIMS traded up $1.75 during trading on Friday, hitting $28.74. The stock had a trading volume of 58,657,137 shares, compared to its average volume of 33,679,875. The company has a market capitalization of $6.55 billion, a PE ratio of 56.35, a P/E/G ratio of 2.31 and a beta of 2.32. The company's 50-day moving average price is $19.60 and its two-hundred day moving average price is $32.66. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $70.43.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business's quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.11 EPS. As a group, sell-side analysts forecast that Hims & Hers Health will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.